Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016
BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in...
Gespeichert in:
Veröffentlicht in: | Euro surveillance : bulletin européen sur les maladies transmissibles 2019-07, Vol.24 (30) |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 30 |
container_start_page | |
container_title | Euro surveillance : bulletin européen sur les maladies transmissibles |
container_volume | 24 |
creator | Ireland, Georgina Mandal, Sema Hickman, Matthew Ramsay, Mary Harris, Ross Simmons, Ruth |
description | BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population. |
doi_str_mv | 10.2807/1560-7917.ES.2019.24.30.1800695 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668288</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31362807</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</originalsourceid><addsrcrecordid>eNpVkVtrGzEQhUVoaW79C0FvbSDeji6r1VJoCcZpCgl5SNpXoZVkW2UtGUl28Et-e3ZJYtKnGTgz3wznIPSFQEUlNN9ILWDStKSpZvcVBdJWlFcMKiIBRFsfoKP9xId3_SE6zvkfAGfQ0k_okBEmRt4RerqNqejelx1OuriM9SqGBfbB-q23G91nbL1ehJidxY--LPHSrXXxxWc8xVufNhl_vZ7-Pf-OdcCxyy5tBzkG3WMTlwMc57Kxuws8C4teB3uBKYDEJQ6ViFP0cT7ccJ9f6wn6czV7mF5Pbu5-_Z5e3kwM56RMCO84EwY60UrrLGuF7QCc4aTTgjVQ19zIeWM6qgWRoqvnYFoGFKyEQWHsBP144a433cpZ40JJulfr5Fc67VTUXv2vBL9Ui7hVQghJpRwAP18AJsWck5vvdwmo0Uo1mq1Gs9XsXo3RKMoVA_UazUA4e__Cfv8tC_YMmSeMLw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Ireland, Georgina ; Mandal, Sema ; Hickman, Matthew ; Ramsay, Mary ; Harris, Ross ; Simmons, Ruth</creator><creatorcontrib>Ireland, Georgina ; Mandal, Sema ; Hickman, Matthew ; Ramsay, Mary ; Harris, Ross ; Simmons, Ruth</creatorcontrib><description>BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.</description><identifier>ISSN: 1560-7917</identifier><identifier>ISSN: 1025-496X</identifier><identifier>EISSN: 1560-7917</identifier><identifier>DOI: 10.2807/1560-7917.ES.2019.24.30.1800695</identifier><identifier>PMID: 31362807</identifier><language>eng</language><publisher>Sweden: European Centre for Disease Prevention and Control (ECDC)</publisher><subject>Adolescent ; Adult ; Aged ; Antiviral Agents - administration & dosage ; Antiviral Agents - therapeutic use ; Cause of Death ; Cohort Studies ; End Stage Liver Disease - complications ; End Stage Liver Disease - mortality ; England - epidemiology ; Female ; Hepacivirus - isolation & purification ; Hepatitis C - diagnosis ; Hepatitis C - drug therapy ; Hepatitis C - mortality ; Humans ; Liver Diseases, Alcoholic - complications ; Liver Diseases, Alcoholic - mortality ; Liver Neoplasms - complications ; Liver Neoplasms - mortality ; Male ; Middle Aged ; Mortality - trends ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - mortality ; Sentinel Surveillance ; Young Adult</subject><ispartof>Euro surveillance : bulletin européen sur les maladies transmissibles, 2019-07, Vol.24 (30)</ispartof><rights>This article is copyright of the authors or their affiliated institutions, 2019. 2019 The authors or their affiliated institutions</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</citedby><cites>FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668288/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668288/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31362807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ireland, Georgina</creatorcontrib><creatorcontrib>Mandal, Sema</creatorcontrib><creatorcontrib>Hickman, Matthew</creatorcontrib><creatorcontrib>Ramsay, Mary</creatorcontrib><creatorcontrib>Harris, Ross</creatorcontrib><creatorcontrib>Simmons, Ruth</creatorcontrib><title>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</title><title>Euro surveillance : bulletin européen sur les maladies transmissibles</title><addtitle>Euro Surveill</addtitle><description>BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cause of Death</subject><subject>Cohort Studies</subject><subject>End Stage Liver Disease - complications</subject><subject>End Stage Liver Disease - mortality</subject><subject>England - epidemiology</subject><subject>Female</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis C - diagnosis</subject><subject>Hepatitis C - drug therapy</subject><subject>Hepatitis C - mortality</subject><subject>Humans</subject><subject>Liver Diseases, Alcoholic - complications</subject><subject>Liver Diseases, Alcoholic - mortality</subject><subject>Liver Neoplasms - complications</subject><subject>Liver Neoplasms - mortality</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mortality - trends</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - mortality</subject><subject>Sentinel Surveillance</subject><subject>Young Adult</subject><issn>1560-7917</issn><issn>1025-496X</issn><issn>1560-7917</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkVtrGzEQhUVoaW79C0FvbSDeji6r1VJoCcZpCgl5SNpXoZVkW2UtGUl28Et-e3ZJYtKnGTgz3wznIPSFQEUlNN9ILWDStKSpZvcVBdJWlFcMKiIBRFsfoKP9xId3_SE6zvkfAGfQ0k_okBEmRt4RerqNqejelx1OuriM9SqGBfbB-q23G91nbL1ehJidxY--LPHSrXXxxWc8xVufNhl_vZ7-Pf-OdcCxyy5tBzkG3WMTlwMc57Kxuws8C4teB3uBKYDEJQ6ViFP0cT7ccJ9f6wn6czV7mF5Pbu5-_Z5e3kwM56RMCO84EwY60UrrLGuF7QCc4aTTgjVQ19zIeWM6qgWRoqvnYFoGFKyEQWHsBP144a433cpZ40JJulfr5Fc67VTUXv2vBL9Ui7hVQghJpRwAP18AJsWck5vvdwmo0Uo1mq1Gs9XsXo3RKMoVA_UazUA4e__Cfv8tC_YMmSeMLw</recordid><startdate>20190725</startdate><enddate>20190725</enddate><creator>Ireland, Georgina</creator><creator>Mandal, Sema</creator><creator>Hickman, Matthew</creator><creator>Ramsay, Mary</creator><creator>Harris, Ross</creator><creator>Simmons, Ruth</creator><general>European Centre for Disease Prevention and Control (ECDC)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20190725</creationdate><title>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</title><author>Ireland, Georgina ; Mandal, Sema ; Hickman, Matthew ; Ramsay, Mary ; Harris, Ross ; Simmons, Ruth</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-14b436c0b698ded396db00ec41ba6370554c8f7cb2a6186b5f0c93020d804c833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cause of Death</topic><topic>Cohort Studies</topic><topic>End Stage Liver Disease - complications</topic><topic>End Stage Liver Disease - mortality</topic><topic>England - epidemiology</topic><topic>Female</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis C - diagnosis</topic><topic>Hepatitis C - drug therapy</topic><topic>Hepatitis C - mortality</topic><topic>Humans</topic><topic>Liver Diseases, Alcoholic - complications</topic><topic>Liver Diseases, Alcoholic - mortality</topic><topic>Liver Neoplasms - complications</topic><topic>Liver Neoplasms - mortality</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mortality - trends</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - mortality</topic><topic>Sentinel Surveillance</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ireland, Georgina</creatorcontrib><creatorcontrib>Mandal, Sema</creatorcontrib><creatorcontrib>Hickman, Matthew</creatorcontrib><creatorcontrib>Ramsay, Mary</creatorcontrib><creatorcontrib>Harris, Ross</creatorcontrib><creatorcontrib>Simmons, Ruth</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ireland, Georgina</au><au>Mandal, Sema</au><au>Hickman, Matthew</au><au>Ramsay, Mary</au><au>Harris, Ross</au><au>Simmons, Ruth</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016</atitle><jtitle>Euro surveillance : bulletin européen sur les maladies transmissibles</jtitle><addtitle>Euro Surveill</addtitle><date>2019-07-25</date><risdate>2019</risdate><volume>24</volume><issue>30</issue><issn>1560-7917</issn><issn>1025-496X</issn><eissn>1560-7917</eissn><abstract>BackgroundMonitoring trends in mortality for individuals diagnosed with hepatitis C virus (HCV) infection are important as we expand treatment and move towards World Health Organization elimination targets.AimTo estimate mortality rates for individuals aged ≥ 15 years diagnosed with HCV infection in England 2008-16.MethodsAn observational cohort study whereby death certificate information was linked to the Sentinel Surveillance of Blood Borne Virus Testing in England. Age-sex standardised mortality rates (ASMR) for individuals diagnosed with HCV infection (2008-16) were calculated and compared to the general population.ResultsOf 43,895 individuals with HCV infection, 2,656 (6.3%) died. All-cause ASMRs were 2,834.2 per 100,000 person years (PY), 2.3 times higher than in the general population. In individuals aged 30-69 years, all-cause mortality rates were 1,768.9 per 100,000 PY among individuals with HCV, 4.7 times higher than in the general population. ASMRs had not decreased between 2010 (2,992) and 2016 (2,340; p=0.10), with no change from 2014 (p = 0.058). ASMRs were 441.0 times higher for hepatitis, 34.4 times higher for liver cancer, 8.1 times higher for end stage liver disease and 6.4 times higher for external causes than in the general population.ConclusionsMortality was higher in individuals with diagnosed HCV infection compared to the general population, highlighting health inequalities. There is a need to improve HCV diagnosis, engagement in care and treatment rates. The high mortality from external causes highlights the importance of integrated health and social care strategies and addressing the needs of this vulnerable population.</abstract><cop>Sweden</cop><pub>European Centre for Disease Prevention and Control (ECDC)</pub><pmid>31362807</pmid><doi>10.2807/1560-7917.ES.2019.24.30.1800695</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1560-7917 |
ispartof | Euro surveillance : bulletin européen sur les maladies transmissibles, 2019-07, Vol.24 (30) |
issn | 1560-7917 1025-496X 1560-7917 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6668288 |
source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Adolescent Adult Aged Antiviral Agents - administration & dosage Antiviral Agents - therapeutic use Cause of Death Cohort Studies End Stage Liver Disease - complications End Stage Liver Disease - mortality England - epidemiology Female Hepacivirus - isolation & purification Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C - mortality Humans Liver Diseases, Alcoholic - complications Liver Diseases, Alcoholic - mortality Liver Neoplasms - complications Liver Neoplasms - mortality Male Middle Aged Mortality - trends Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - mortality Sentinel Surveillance Young Adult |
title | Mortality rates among individuals diagnosed with hepatitis C virus (HCV); an observational cohort study, England, 2008 to 2016 |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T00%3A54%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mortality%20rates%20among%20individuals%20diagnosed%20with%20hepatitis%20C%20virus%20(HCV);%20an%20observational%20cohort%20study,%20England,%202008%20to%202016&rft.jtitle=Euro%20surveillance%20:%20bulletin%20europ%C3%A9en%20sur%20les%20maladies%20transmissibles&rft.au=Ireland,%20Georgina&rft.date=2019-07-25&rft.volume=24&rft.issue=30&rft.issn=1560-7917&rft.eissn=1560-7917&rft_id=info:doi/10.2807/1560-7917.ES.2019.24.30.1800695&rft_dat=%3Cpubmed_cross%3E31362807%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31362807&rfr_iscdi=true |